menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Fresenius Receives FDA Approval for their Denosumab Biosimilars

    BUSINESSWIRE

    Fresenius Kabi`s Biologic Bomyntra Receives Approval in US

    FDA

    Fresenius Kabi`s Biologic Conexxence Receives Approval in US

    FDA

    Fresenius Kabi`s Biologic Denosumab Receives Approval in US

    FDA

    City of Hope Trials Bone Medication for Early Type 1 Diabetes

    BUSINESSWIRE

    Alvotech & Dr. Reddy’s Announce FDA acceptance of BLA for AVT03

    PRESS RELEASE

    Celltrion receives FDA approval for Stoboclo & Osenvelt

    PR NEWSWIRE

    FDA Accepts Amneal’s BLA for Two Denosumab Biosimilars

    BUSINESSWIRE

    Celltrion Expands EU Biosimilar Portfolio With Two New Approvals

    BUSINESSWIRE

    Samsung Bioepis Gains EC Approval for Denosumab Biosimilar

    BUSINESSWIRE

    FDA Approves Samsung Bioepis’ Ospomyv, Xbryk

    BUSINESSWIRE

    Samsung Bioepis`s Biologic Xbryk Receives Approval in US

    FDA

    GlycoNex Doses 1st Patient in Ph 3 Trial for Denosumab Biosimilar

    PR NEWSWIRE

    Celltrion Presents Phase III Data for CT-41 & CT-P47 Biosimilars

    PR NEWSWIRE

    Samsung Gets Positive CHMP Opinion for Denosumab Biosimilars

    GLOBENEWSWIRE

    Sandoz`s Biologic Jubbonti (Denosumab-bbdz) Receives Suppl Approval in US

    FDA

    Sandoz`s Biologic Wyost (Denosumab-bbdz) Receives Suppl Approval in US

    FDA

    EMA Accepts AVT03 Marketing Application For Prolia Biosimilar

    GLOBENEWSWIRE

    Teva Prolia Biosimilar Accepted For Review By FDA And EMA

    GLOBENEWSWIRE

    STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In EU

    GLOBENEWSWIRE

    Alvotech Reports Positive Results For AVT03, Biosimilar To Prolia And Xgeva

    GLOBENEWSWIRE

    Alvotech and STADA add to strategic alliance through denosumab partnership

    PRESS RELEASE

    Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024

    GLOBENEWSWIRE

    Dr. Reddy’s and Novartis sign distribution agreement for anti-diabetes products

    PHARMACEUTICAL TECHNOLOGY

    Henlius Xgeva® Prolia® Biosimilar: Ema Filings With Organon Validated

    BUSINESSWIRE

    EC approves Sandoz’s biosimilars for bone-related ailments

    PHARMACEUTICAL TECHNOLOGY

    Sandoz’s Wyost and Jubbonti Granted EC Marketing Authorization

    GLOBENEWSWIRE

    Alvotech, Dr. Reddy`s ink pact for commercialisation of denosumab

    PRESS RELEASE

    MAIWEIJIAN becomes first approved biosimilar of Denosumab (120mg) in China

    BIOSPECTRUMASIA

    MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

    PR NEWSWIRE

    Phase 3 Comparative Clinical Study of Prolia® and Xgeva Met Primary Endpoints

    BUSINESSWIRE

    Sandoz wins FDA approval for first two biosimilars for Amgen`s bone drug

    ENDPTS

    Sandoz`s Biologic Jubbonti (denosumab-bbdz) Receives Approval in the U.S.

    FDA

    Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar

    PR NEWSWIRE

    FDA slaps boxed warning on Amgen`s osteoporosis drug Prolia

    FIERCE PHARMA

    Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline

    BUSINESSWIRE

    Sandoz Marketing Authorization Applications for denosumab accepted by EMA

    GLOBENEWSWIRE

    New Data From Amgen`S Prolia® (Denosumab) Demonstrates Significant Reduction

    PR NEWSWIRE

    Amgen takes Novartis` Sandoz to court over bone med biosimilar

    FIERCE PHARMA

    Amgen`s denosumab shows promise in small, NIH-funded rare bone disease study

    ENDPTS

    The World`s Second Approved Biosimilars of Denosumab (MAILISHU)

    PR NEWSWIRE

    Sandoz License Application for proposed biosimilar denosumab accepted by US FDA

    GLOBENEWSWIRE

    BeiGene Announces Expansion of Coverage on China’s Reimbursement Drug List

    PRESS RELEASE

    Amgen`s Biologic Prolia (Denosumab) Receives Approval in U.S.

    FDA

    Mabwell Partners with Binnopharm to Market 9MW0113, 9MW0321 and 9MW0311

    PR NEWSWIRE

    Prolia (denosumab) by Amgen: Drug Safety Communication - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis

    FDA

    Sandoz announces further progress on its biosimilar pipeline,release +ve results

    GLOBENEWSWIRE

    Lupin, DKSH enter pact to commercials Alvotech biosimilars in Philippines

    ECONOMIC TIMES

    Lupin and DKSH sign exclusive licensing and supply agreement to market five

    EXPRESS PHARMA

    Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab

    RAPS

    Lupin, I’rom pharma enter into licensing agreement for Denosumab biosimilar

    HEALTH ET

    Amgen’s marketing for cancer bone med Xgeva shifts to patients’ stories

    ENDPTS

    Richter, Hikma sign excl. commercialisation & license agreement for denosumab

    PRNEWSWIRE

    Theramex announces license agreement for Prolia biosimilar in EU and Australia

    GOODWIN

    Theramex UK announces a license and supply agreement with Enzene Biosciences

    PHARMIWEB

    China makes new inclusions in national reimbursement drug list

    BIOSPECTRUMASIA

    China makes new inclusions in national reimbursement drug list

    BIOSPECTRUMASIA

    Luye Pharma Starts a Phase III Clinical Study for Denosumab Injection (LY01011)

    LUYE

    Could Amgen`s Xgeva boost immunotherapy in breast cancer?

    FIERCEBIOTECH

    BeiGene Announces the Approval of XGEVA® (Denosumab) in China

    BIOSPACE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.